Patient Dosing Begins in Phase 2 Trial of MCLA-128 in Metastatic Breast Cancer
News
The first patient in the Phase 2 clinical study of MCLA-128 in metastatic breast cancer patients has been dosed, The Netherlands-based immuno-oncology company Merus recently announced. The international study (NCT03321981) ... Read more